BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with life-threatening diseases. Our principal technology platform centers on targeted protein degradation, as well as PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. This technology is designed to utilize the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a broad range of diseases, including targets that have to date been considered ‘undruggable’.
Location: United States, New York
Employees: 11-50
Total raised: $127M
Founded date: 2008
Investors 2
| Date | Name | Website |
| 08.11.2021 | Lumira Ven... | lumiravent... |
| 15.09.2021 | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.06.2021 | Series E | $92M | - |
| 28.07.2020 | Series D | $35M | - |
Mentions in press and media 12
| Date | Title | Description |
| 06.08.2021 | BioTheryX Announces Appointments of Three New Members to its Board of Directors | |
| 09.06.2021 | BioTheryX Announces First Patient Dosed with BTX-A51 in Phase 1 Clinical Trial in Patients with Advanced Solid Tumors | |
| 20.05.2021 | BioTheryX has announced a $92M Series E to accelerate development of its targeted protein degradation pipeline and technology platform in oncology | - |
| 20.05.2021 | BioTheryX Gets $92M | San Diego-based BioTheryX, which is developing protein degradation technology for use in creating cancer medicines, has raised $92M in a Series E funding round, according to the company. The funding was led by Farallon Capital Management, a... |
| 20.05.2021 | BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology | |
| 18.05.2021 | BioTheryX Announces Expansion of Scientific Advisory Board with Appointment of Brenda Schulman | |
| 07.04.2021 | BioTheryX Announces Expansion of Scientific Advisory Board | |
| 01.02.2021 | BioTheryX Appoints Jamie Donadio as Chief Financial Officer | |
| 29.07.2020 | BioTheryX Finds $35M More | San Diego-based BioTheryX, a biotechnology company focused on protein modulation, has raised $35M in a Series D funding, the company said on Tuesday. The funding was led by MSD Partners, L.P. According to the company, Robert Platek, a Partn... |
| 28.07.2020 | BioTheryX Receives $35M | SAN DIEGO, CA, BioTheryX today announced it has closed a $35 million Series D financing. >> Click here for more funding data on BioTheryX >> To export BioTheryX funding data to PDF and Excel, click here BioTheryX, a clini... |
Show more